Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

01-12-2020 | Obesity | Research article

Changes in plasma aldosterone level after weight loss by bariatric surgery in morbidly obese patients

Authors: Preaw Suwannasrisuk, Patchaya Boonchaya-anant, Natnicha Houngngam, Suthep Udomsawaengsup, Sarat Sunthornyothin

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Overactivation of renin-aldosterone-angiotensin system (RAS) is part of the pathogenesis of obesity-associated hypertension. Evidences have shown that weight loss can result in reduction in blood pressure and RAS. This study was aim to investigate changes of plasma aldosterone concentration (PAC) after bariatric surgery.

Methods

A prospective study was done in 14 morbidly obese patients undergoing bariatric surgery. Patients who were taking medications that can interfere with PAC and renin levels were excluded. Collection of blood samples were done at baseline and at 3 and 6-month post-bariatric surgery.

Results

Four out of 14 patients had hypertension at baseline. Mean body mass index (BMI) was 56.7 ± 13.5 kg/m2. PAC were significantly decreased at 3-and 6-month post-bariatric surgery from 14.3 ± 8.0 to 7.5 ± 5.5 [reduction of 36% from baseline (P < 0.01)] and 8.0 ± 6.6 ng/dl [reduction of 32% from baseline (P < 0.05)] respectively. The reduction of PAC at 3-month post-surgery was correlated with the reduction of body weight (r = 0.46, P < 0.05), waist circumference (r = 0.73, P < 0.05) and percent of body fat (r = 0.58, P < 0.05).

Conclusions

Maximal reduction of PAC in obese patients underwent bariatric surgery occurred during the first 3 months after bariatric surgery. The reduction of PAC was associated with the reduction of body weight, waist circumference and percent of body fat suggesting the link between RAS and obesity-mediated hypertension.
Literature
1.
go back to reference Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804–14.CrossRef Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804–14.CrossRef
2.
go back to reference Aekplakorn W, Mo-Suwan L. Prevalence of obesity in Thailand. Obes Rev. 2009 Nov;10(6):589–92.CrossRef Aekplakorn W, Mo-Suwan L. Prevalence of obesity in Thailand. Obes Rev. 2009 Nov;10(6):589–92.CrossRef
3.
go back to reference Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35(1):4–16.CrossRef Kalil GZ, Haynes WG. Sympathetic nervous system in obesity-related hypertension: mechanisms and clinical implications. Hypertens Res. 2012;35(1):4–16.CrossRef
4.
go back to reference Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548–56.CrossRef Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548–56.CrossRef
5.
go back to reference Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83(2):461S–5S.CrossRef Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 2006;83(2):461S–5S.CrossRef
6.
go back to reference Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15(14):2727–9.CrossRef Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15(14):2727–9.CrossRef
7.
go back to reference Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev. 2012;13(2):136–49.CrossRef Kalupahana NS, Moustaid-Moussa N. The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obes Rev. 2012;13(2):136–49.CrossRef
8.
go back to reference Northcott CA, Fink GD, Garver H, et al. The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity. Endocrinology. 2012 Apr;153(4):1764–73.CrossRef Northcott CA, Fink GD, Garver H, et al. The development of hypertension and hyperaldosteronism in a rodent model of life-long obesity. Endocrinology. 2012 Apr;153(4):1764–73.CrossRef
9.
go back to reference Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int Suppl. 2011;79(2):162–8.CrossRef Yvan-Charvet L, Quignard-Boulange A. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney Int Suppl. 2011;79(2):162–8.CrossRef
10.
go back to reference Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62.CrossRef Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62.CrossRef
11.
go back to reference Tuck ML. The effect of weight reduction on blood pressure, plasma renin activity and plasma aldosterone levels on obese patients. N Engl J Med. 1981;304:16.CrossRef Tuck ML. The effect of weight reduction on blood pressure, plasma renin activity and plasma aldosterone levels on obese patients. N Engl J Med. 1981;304:16.CrossRef
12.
go back to reference Ruano M. Morbid obesity ,hypertensive disease and the renin angiotensin aldosterone axis. Obes Surg. 2005;15:670–6.CrossRef Ruano M. Morbid obesity ,hypertensive disease and the renin angiotensin aldosterone axis. Obes Surg. 2005;15:670–6.CrossRef
13.
go back to reference Dall'Asta C, Vedani P, Manunta P, et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovas Dis. 2009 Feb;19(2):110–4.CrossRef Dall'Asta C, Vedani P, Manunta P, et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovas Dis. 2009 Feb;19(2):110–4.CrossRef
14.
go back to reference National Institute of Health. Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25–7,1991. Nutrition. 1996;12(6):397–404. National Institute of Health. Gastrointestinal surgery for severe obesity. NIH consensus development conference, March 25–7,1991. Nutrition. 1996;12(6):397–404.
15.
go back to reference Flores L, Vidal J, Nunez I, et al. Longitudinal changes of blood pressure after weight loss: factors involved. Surg Obes Relat Dis. 2015;11(1):215–21.CrossRef Flores L, Vidal J, Nunez I, et al. Longitudinal changes of blood pressure after weight loss: factors involved. Surg Obes Relat Dis. 2015;11(1):215–21.CrossRef
16.
go back to reference Bluher S, Mantzoros CS. The role of leptin in regulating neuroendocrine function in humans. J Nutr. 2004;134(9):2469S–74S.CrossRef Bluher S, Mantzoros CS. The role of leptin in regulating neuroendocrine function in humans. J Nutr. 2004;134(9):2469S–74S.CrossRef
17.
go back to reference Terra X, Auguet T, Guiu-Jurado E, et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2013;23(11):1790–8.CrossRef Terra X, Auguet T, Guiu-Jurado E, et al. Long-term changes in leptin, chemerin and ghrelin levels following different bariatric surgery procedures: roux-en-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2013;23(11):1790–8.CrossRef
18.
go back to reference Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110(4):571–84.CrossRef Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110(4):571–84.CrossRef
19.
go back to reference Chen X, Zhang SL, Pang L, et al. Characterization of a putative insulin-responsive element and its binding protein(s) in rat angiotensinogen gene promoter: regulation by glucose and insulin. Endocrinology. 2001;142(6):2577–85.CrossRef Chen X, Zhang SL, Pang L, et al. Characterization of a putative insulin-responsive element and its binding protein(s) in rat angiotensinogen gene promoter: regulation by glucose and insulin. Endocrinology. 2001;142(6):2577–85.CrossRef
20.
go back to reference Jones BH, Standridge MK, Taylor JW, et al. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Phys. 1997;273(1 Pt 2):R236–42. Jones BH, Standridge MK, Taylor JW, et al. Angiotensinogen gene expression in adipose tissue: analysis of obese models and hormonal and nutritional control. Am J Phys. 1997;273(1 Pt 2):R236–42.
21.
go back to reference Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132–42.CrossRef Schiavon CA, Bersch-Ferreira AC, Santucci EV, et al. Effects of Bariatric Surgery in Obese Patients With Hypertension: The GATEWAY Randomized Trial (Gastric Bypass to Treat Obese Patients With Steady Hypertension). Circulation. 2018;137(11):1132–42.CrossRef
22.
go back to reference Nosso G, Griffo E, Cotugno M, et al. Comparative effects of roux-en-Y gastric bypass and sleeve Gastrectomy on glucose homeostasis and Incretin hormones in obese type 2 diabetic patients: a one-year prospective study. Horm Metab Res. 2016;48(5):312–7.CrossRef Nosso G, Griffo E, Cotugno M, et al. Comparative effects of roux-en-Y gastric bypass and sleeve Gastrectomy on glucose homeostasis and Incretin hormones in obese type 2 diabetic patients: a one-year prospective study. Horm Metab Res. 2016;48(5):312–7.CrossRef
23.
go back to reference Ryo M, Maeda K, Onda T, et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care. 2005;28(2):451–3.CrossRef Ryo M, Maeda K, Onda T, et al. A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care. 2005;28(2):451–3.CrossRef
24.
go back to reference Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. 2004;23(6):1430–53.CrossRef Kyle UG, Bosaeus I, De Lorenzo AD, et al. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin Nutr. 2004;23(6):1430–53.CrossRef
Metadata
Title
Changes in plasma aldosterone level after weight loss by bariatric surgery in morbidly obese patients
Authors
Preaw Suwannasrisuk
Patchaya Boonchaya-anant
Natnicha Houngngam
Suthep Udomsawaengsup
Sarat Sunthornyothin
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-0527-4

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.